Loss of PI5P4Kα Slows the Progression of a Pten Mutant Basal Cell Model of Prostate Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Targeting phosphatidylinositol 5-phosphate 4-kinase alpha (PI5P4Kα) in prostate basal cells slows PTEN-mutant prostate cancer progression. This metabolic enzyme disruption impacts lipid metabolism, offering a new therapeutic target for advanced prostate cancer.
Area Of Science
- Urology
- Oncology
- Molecular Biology
Background
- Early prostate cancer relies on androgen receptor signaling in luminal cells.
- The role of basal cells in prostate cancer progression is not fully understood.
- Phosphatidylinositol 5-phosphate 4-kinase alpha (PI5P4Kα) is a metabolic enzyme with cell type-specific importance in the prostate.
Purpose Of The Study
- To investigate the role of PI5P4Kα in prostate basal cells.
- To develop a basal cell-specific mouse model for studying PI5P4Kα function.
- To explore PI5P4Kα as a potential therapeutic target for PTEN-mutant prostate cancer.
Main Methods
- Development of basal cell-specific genetically engineered mouse models targeting Pip4k2a and Pten.
- Lineage tracing and single-cell RNA sequencing to analyze cellular changes.
- Transcriptomic pathway analysis and lipid metabolism assays in prostate cancer cells.
Main Results
- PI5P4Kα is enriched in prostate basal cells.
- Combined loss of Pip4k2a and Pten slowed prostatic intraepithelial neoplasia development in mice.
- Downregulation of Pip4k2a disrupted lipid metabolism and reduced tumor progression.
- Shifts in carnitine lipids were observed in LNCaP cells treated with siPIP4K2A.
Conclusions
- PI5P4Kα plays a significant role in prostate basal cells.
- Targeted loss of PI5P4Kα inhibits PTEN-mutant prostate cancer progression.
- PI5P4Kα is a promising therapeutic target for PTEN-mutant prostate cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...